Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-04-13

FDA Approved: VARUBI — Supplemental Application (TerSera Therapeutics LLC)

View source ↗

Summary

FDA approved a supplemental application for VARUBI (rolapitant) submitted by TerSera Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VARUBI (rolapitant)

Snippet

SUPPL AP for VARUBI (ROLAPITANT)